H. Zetterberg

Correlation of blood biomarkers with microstructural brain injury in survivors of out-of-hospital cardiac arrest

In-hospital mortality among resuscitated out-of-hospital cardiac arrest (OHCA) patients remains high. Identifying patients who will benefit from intensive care while avoiding prolonged, potentially unnecessary treatments is essential. Blood-based biomarkers provide a novel method for evaluating brain injury. The abil...

Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease

Abstract INTRODUCTION Mounting evidence suggests overlapping pathology across Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's disease (PD), yet its extent and clinical implications remain unclear. METHODS Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40, phosphorylated tau 181 (p‐tau181), neu...

A single-center open-label, randomized, parallel-group controlled clinical trial on the long-term effect of the treatment with EGb 761 in blood markers of inflammation and neurodegeneration in patients with mild cognitive impairment: ACE-2020-EGb 761.

BackgroundNeuroinflammation plays a central role in Alzheimer's disease (AD) pathology and other dementias. EGb 761, a standardized Ginkgo biloba extract, has shown potential anti-inflammatory and neuroprotective properties.ObjectiveThis study evaluated the effects of EGb 761 on plasma proteins related to inflammation...

Big tau and brain-derived tau reveal peripheral and central nervous system involvement in neuropathies

INTRODUCTION: Biomarkers for monitoring disease activity and treatment response in peripheral neuropathies remain limited. Big tau, a high-molecular-weight isoform of tau, is predominantly expressed in the peripheral nervous system (PNS). We investigated serum levels of big tau, brain-derived tau (BD-tau), and neurofil...

Natural History and Clinical Associations of Plasma Interleukin-6 Levels in Traumatic Brain Injury

Inflammation following traumatic brain injury (TBI) may contribute to long-term morbidity. We aimed to characterize plasma interleukin-6 (IL6) trajectory after TBI and assess associations with imaging, biomarkers, and outcomes. Secondary analysis of three prospective multicenter observational cohorts: BIO-AX-TBI (Unite...

Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers

Alzheimer’s disease (AD) develops silently for years before symptoms emerge, making early identification of at-risk individuals essential for prevention trials and early intervention. We tested whether combining neurophysiological, imaging, and blood biomarkers improves prediction of progression to mild cognitive impai...

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs

Results show that, irrespective of the partner antibody, phosphorylated tau assays are more accurate than assays that also measure non-phosphorylated forms of the protein in differentiating Aβ + from Aβ − individuals, and indicate that BD-pTau217 may offer superior sensitivity for the early identification of AD patholo...

CSF proteomic quantitative trait loci mapping reveals genetic insights into Alzheimer’s disease

Many AD pQTLs in CSF were enriched in neuroimmune activation, suggesting a genetic basis for neuroimmune dysregulation in AD, and how genetic variation shapes protein expression in the central nervous system is highlighted.

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.

Plasma p-tau217 and NfL predict incident dementia in the community

These findings support the use of blood-based biomarkers for population-level dementia risk stratification, underscore the value of combining markers to improve prognostic precision, and can aid clinicians using plasma p-tau217 or NfL in interpreting dementia risk.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

It is suggested that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.